InspireMD, Inc. (NSPR) stock
NSPRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 10/3054% below fair value
$0.64−0.13 (-16.78%)
Close on Nov 13, 2026Market cap $29.94MP/E –Yield –
InspireMD r&d expenses
Research and development expenses are spending on new products and technology.
InspireMD's R&D Expenses for the twelve months ending Jun 30, 2026 was $16.17M, up 4.3% year over year. For fiscal 2025 it was $15.00M, up 10.0% from the year before. Over ten years it grew 15.2% a year on average. The highest annual figure on record is $15.00M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.00M | +10.0% |
| FY2024 | Dec 31, 2024 | $13.63M | +70.8% |
| FY2023 | Dec 31, 2023 | $7.98M | +2.2% |
| FY2022 | Dec 31, 2022 | $7.81M | +51.4% |
| FY2021 | Dec 31, 2021 | $5.16M | +131.0% |
| FY2020 | Dec 31, 2020 | $2.23M | -24.4% |
| FY2019 | Dec 31, 2019 | $2.95M | +92.4% |
| FY2018 | Dec 31, 2018 | $1.54M | +20.3% |
| FY2017 | Dec 31, 2017 | $1.28M | -1.2% |
| FY2016 | Dec 31, 2016 | $1.29M | -64.6% |
| FY2015 | Dec 31, 2015 | $3.64M | -12.4% |
| FY2013 | Jun 30, 2013 | $4.16M | +210.6% |
| FY2010 | Dec 31, 2010 | $1.34M | +0.6% |
| FY2009 | Dec 31, 2009 | $1.33M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.30M | +12.0% |
| Q1 FY2026 | Mar 31, 2026 | $4.76M | +17.3% |
| Q4 FY2025 | Dec 31, 2025 | $3.48M | -5.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.64M | -7.2% |
| Q2 FY2025 | Jun 30, 2025 | $3.83M | +12.7% |
| Q1 FY2025 | Mar 31, 2025 | $4.06M | +54.6% |
| Q4 FY2024 | Dec 31, 2024 | $3.69M | +81.5% |
| Q3 FY2024 | Sep 30, 2024 | $3.92M | +85.5% |
| Q2 FY2024 | Jun 30, 2024 | $3.40M | +70.6% |
| Q1 FY2024 | Mar 31, 2024 | $2.63M | +42.4% |
| Q4 FY2023 | Dec 31, 2023 | $2.04M | +1.1% |
| Q3 FY2023 | Sep 30, 2023 | $2.11M | +2.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.99M | -3.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.84M | +9.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.01M | +31.2% |
| Q3 FY2022 | Sep 30, 2022 | $2.06M | +37.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.06M | +59.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.68M | +100.2% |
| Q4 FY2021 | Dec 31, 2021 | $1.53M | +113.1% |
| Q3 FY2021 | Sep 30, 2021 | $1.50M | +173.8% |
| Q2 FY2021 | Jun 30, 2021 | $1.29M | +190.5% |
| Q1 FY2021 | Mar 31, 2021 | $839.00K | +60.4% |
| Q4 FY2020 | Dec 31, 2020 | $720.00K | +37.9% |
| Q3 FY2020 | Sep 30, 2020 | $546.00K | +23.5% |
| Q2 FY2020 | Jun 30, 2020 | $444.00K | -48.7% |
| Q1 FY2020 | Mar 31, 2020 | $523.00K | -53.5% |
| Q4 FY2019 | Dec 31, 2019 | $522.00K | -18.1% |
| Q3 FY2019 | Sep 30, 2019 | $442.00K | +6.3% |
| Q2 FY2019 | Jun 30, 2019 | $865.00K | +276.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.13M | +346.4% |
| Q4 FY2018 | Dec 31, 2018 | $637.00K | +171.1% |
| Q3 FY2018 | Sep 30, 2018 | $416.00K | +44.4% |
| Q2 FY2018 | Jun 30, 2018 | $230.00K | -42.9% |
| Q1 FY2018 | Mar 31, 2018 | $252.00K | -28.0% |
| Q4 FY2017 | Dec 31, 2017 | $235.00K | -31.9% |
| Q3 FY2017 | Sep 30, 2017 | $288.00K | -0.3% |
| Q2 FY2017 | Jun 30, 2017 | $403.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $350.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $345.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $289.00K | – |
See a number that looks wrong?